Effectiveness of Rituximab in Severe Wegener’s Granulomatosis: Report of Two Cases and Review of the Literature

Joaquim Oristrell*, Guillermina Bejarano, Rosa Jordana, Manuel Monteagudo, Begoña Marí, Arnau Casanovas, Carles Tolosa
Internal Medicine Service, Hospital de Sabadell, Corporació Parc Taulí, Universitat Autònoma de Barcelona (UAB), Spain

© Oristrell et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Corporació Parc Taulí, Parc Tauli s/n, 08208 Sabadell, Barcelona, Spain; Tel: + 34-937 458 252; Fax: 34-937 160 646; E-mail:


We hereby describe the satisfactory evolution of rituximab treatment in two patients with Wegener’s granulomatosis (WG). Rituximab was indicated for refractoriness to standard treatment in one case and life-threatening myelotoxicity due to alkylating agents in the other. A brief review of previous experience with the use of rituximab in the treatment of WG is presented.

Keywords: Rituximab, Wegener’s granulomatosis, rescue treatment..